Skip to content

Study · Not a test of the peptide alone · 2005

1 result

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M

Pharmacological research1 Mar 2005Cited by 9 (Europe PMC)

PMID15661579 (opens in a new tab)DOI10.1016/j.phrs.2004.09.006 (opens in a new tab)PepBankPUB-15661579
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01LabNot a test of Oxytocin aloneIn vitro (cells)Activity measurement

    In human uterine smooth muscle cells, the V1A antagonist YM218 inhibited the oxytocin-induced calcium increase only weakly, with an IC50 of 607 nM.

    In plain wordsIn cells, a test drug blocked oxytocin's calcium signal only weakly.

    Peptide
    Oxytocin
    Outcome
    DecreaseYM218 inhibition of oxytocin-induced intracellular calcium increase
    Study

    humann: not reported in source

    Human uterine smooth muscle cells
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    IC50
    607 nM
    YM218 versus oxytocin-induced [Ca2+]i in human USMCs

    Source sentences

    Summary
    in human USMCs expressing oxytocin receptors, YM218 exhibited a much lower potency in inhibiting the oxytocin-induced [Ca(2+)](i) increase, showing an IC(50) value of 607 nM
    1 context sentence
    Summary · context
    The binding and signal transduction characteristics of YM218 ((Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene]-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl}-2-methyl-3-furanilide hemifumarate), a newly synthesized, potent arginine vasopressin (AVP) V(1A) receptor-selective anta…

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.